Navigation Links
Pharmacyclics Secures $5.0 Million in Debt Financing
Date:1/6/2009

SUNNYVALE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that in preparation of further equity offerings, Robert W. Duggan & Associates ("RWD") made an unsecured loan to Pharmacyclics, Inc. on December 30, 2008, in the amount of $5,000,000. As of December 31, 2008, the company's cash and cash equivalents totaled approximately $12.9 million, including the $5,000,000 in loan proceeds. RWD is controlled by Pharmacyclics' Chairman of the Board and interim Chief Executive Officer, Chief Financial Officer and Secretary, Robert W. Duggan. Mr. Duggan is the beneficial owner of approximately 29% of Pharmacyclics' outstanding common stock.

Under the terms of the loan, Pharmacyclics is to pay RWD the principal sum of $5,000,000 on the earlier of (i) July 1, 2010 or (ii) upon the closing of an equity offering or rights offering by Pharmacyclics. The loan bears interest as follows: (i) 1.36% from December 30, 2008 until March 31, 2009, (ii) the rate of interest in effect for such day as publicly announced from time to time by Citibank N.A. as its "prime rate" from April 1, 2009 until December 31, 2009 and (iii) the prime rate plus 2% from January 1, 2010 until the expiration of the loan. Interest is to be paid annually.

Mr. Duggan commented, "While the global economy is in unchartered waters and forecasts concerning the future are all over the map, it is important to keep in mind that companies like Pharmacyclics continue to discover and develop innovative medicines to treat serious, unmet worldwide medical needs. As a practical matter almost every country, company, organization and individual that make up this economy of ours is presently very engaged in plotting a course of action that creates prosperity and forward progress for their shareholders, for their employees,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
2. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. Pharmacyclics Announces It Received Nasdaq Notification
5. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 EvoDerma ’s NOOME Anti-Aging Motion ... device now comes with a second treatment cup to help ... The new cup is thinner on the edges for a ... rough, thin and uneven surfaces on the face, neck and ... stimulating treatment on areas such as the cheeks and neck, ...
(Date:7/10/2014)... 10, 2014  Kainos Capital, a firm specializing in ... that it has acquired the Slim-Fast brand from Unilever. ... Terms of the transaction were not disclosed. ... business that markets ready-to-drink shakes, powders, bars and snacks ... and in the United Kingdom ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
(Date:7/10/2014)... disorders has been extremely challenging because there are many ... to cause disease. Now investigators reporting in the July ... Stem Cell describe a strategy that may help ... risk factors or environmental exposures to affect the development ... variant that may predispose individuals to schizophrenia. , ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2
... is available in French . , A new nanotech ... Moores and their colleagues offers industry an opportunity to ... Catalysts are substances used to facilitate and drive chemical ... ecological and economic impact of traditional chemical catalysts and ...
... , HUNTSVILLE, Ala. , Feb. ... Prime Contractor for the $485 million five-year ... the full and open, large business category of competition. ... Support, and Program and Integration Support to the Edgewood ...
... CRANBURY, N.J. , Feb. 16 Palatin Technologies, Inc. (NYSE Amex: ... 31, 2009 .  Palatin reported net income of $4.5 million , or ... December 31, 2009 , compared to a net loss of $0.4 million ... period in 2008.  Total revenues in the quarter ended December 31, 2009 ...
Cached Biology Technology:Camber Wins ECBC Mission Support Contract 2Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 2Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 3Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 4Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 5Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 6Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010 7
(Date:7/11/2014)... of Entiat on Tuesday, July 8, 2014. Despite the ... over 1,000 acres by evening. Three outbuildings were damaged. ... the Washington Department of Natural Resources. The fire ... fire control strategies and tactics. Other cooperators include the ... Resources, (WA DNR), Bureau of Land Management, Chelan County ...
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2
... Ill. A protein found in the membranes of ... offer a new way of using sunlight to generate ... by researchers at the U.S. Department of Energy,s Argonne ... colleagues combined a pigment called bacteriorhodopsin with semiconducting nanoparticles ...
... 2013 Research and Markets ( http://www.researchandmarkets.com/research/938bt4/iris_biometrics ... Biometrics - Global Strategic Business Report" report to ... This report analyzes the worldwide markets for ... separate comprehensive analytics for the US, Japan ...
... were working on something at your computer and a gorilla ... would like to think yes, however, research shows that people ... This is a phenomenon known as inattentional blindness (IB). In ... Boston, researchers have found that even expert searchers, operating in ...
Cached Biology News:Purple sunlight eaters 2Iris Biometrics - Global Strategic Business Report 2If you're not looking for it, you probably won't see it 2
IHC Zinc Fixative - , 1000 ml Consult technical datasheet for details....
Harmful, Irritant, Combustible ,DEPC...
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Prim...
Biology Products: